Presentation to Highlight Single-Dose MVA and Continuous Cell-Line MVA Manufacturing Innovations ATLANTA, GA - October 6, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunothe...
Study Shows Protection Against Highly Pathogenic Clade I Mpox Virus and Durable CD8+ T-Cell Responses Findings Support GeoVax's Broader Strategy to Expand the Utility of the MVA Vaccine Platform ATLANTA, GA - September 21, 2026 (NEWMEDIAWIRE) - GeoVa...
BDBV-Specific Construct Developed Using GeoVax Proprietary Rapid Cloning Technology and Builds on Established Filovirus Vaccine Experience GEO-MVA (Mpox/Smallpox Vaccine) Targeted for Phase 3 Initiation Remains Company Priority ATLANTA, GA - Septembe...
Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program Advances GeoVax's Strategy to Expand and Diversify MVA Vaccine Supply ATLANTA, GA - September 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology c...
Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.
ATLANTA, GA - September 10, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, today provided an...
Gavi-funded, ICG-Coordinated Initiative Establishes Long-Term Infrastructure for Timely and Equitable Mpox Vaccine Access During Outbreaks New Stockpile Framework Supports Sustainable Supply and Long-Term Global Preparedness ATLANTA, GA - September 9...
Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.
ATLANTA, GA - August 26, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an existing institutio...
Selections of CRO and European Clinical Sites Represent Significant Milestones Toward Initiation of the GEO-MVA Immunobridging Study ATLANTA, GA - August 25, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology compa...
Emerging Evidence of Potential Protection From Authorized Ebola Zaire Vaccine Against Bundibugyo Virus Provides Rationale for Evaluating GeoVax's MVA-Based Ebola Vaccine Candidates ATLANTA, GA - August 24, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nas...
Moderna-Merck Positive Phase 3 Combination Results Reinforce Strategic Rationale for Planned Gedeptin(R) + KEYTRUDA(R) Study ATLANTA, GA - August 24, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company devel...
This is the newest page. Registered accounts read further back.